Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2017

View Archived Issues

Opiant receives FDA feedback on development of OPNT-002 for alcohol use disorder

Novel fixed dose combination EHCV shows promise against chronic hepatitis C in clinical study

Amgen reports overall survival data from ENDEAVOUR study of Kyprolis

GS-PI-1 is a promising new generation HIV PI with favorable potency and resistance barrier

Promising results from the BCN02-Romi study of MVA.HIVconsv vaccine

Invenra and QIMR Berghofer collaborate to discover therapeutic antibodies

Bristol-Myers Squibb announces investment and plans for collaboration with Grail

EMA grants PRIME access to givosiran for acute hepatic porphyrias

European Commission approves Vihuma

European Commission grants orphan drug designation to apatinib for gastric cancer

Audentes initiates LUSTRO study in Crigler-Najjar syndrome

Pivotal Phase III study results for Merck & Co.'s varicella zoster virus vaccine presented

Arrakis Therapeutics completes Series A financing

SB-913 from Sangamo Therapeutics granted U.S. orphan drug designation for the treatment of MPS II

Boehringer Ingelheim's BI-836858 given U.S. orphan drug designation for the treatment of MDS

Sellas reports updated phase II data on galinpepimut-S in multiple myeloma

European Commission grants orphan drug designation to ZX-008 for Lennox-Gastaut syndrome

FDA grants priority review to enasidenib NDA

Pfizer and iTeos Therapeutics identify tryptophan 2,3-dioxygenase inhibitors

Eli Lilly completes acquisition of CoLucid Pharmaceuticals

Hetero Research Foundation discloses novel antiviral agents

FDA allows PR-022 to proceed to phase II study for the treatment of atopic dermatitis

Myovant initiates phase III trial of relugolix for advanced prostate cancer

Toray Industries initiates first-in-human study of TRK-950 in advanced solid tumors

Intensity Therapeutics studies intratumorally dosed INT-230-6 in advanced cancers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...